Skip to main content

Advertisement

Table 3 Characteristics of systematic reviews comparing triple therapy with different antibiotics (n = 8)

From: Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis

Author, Year, country Last search date Disease Countries of included RCTsc Intervention Comparator No. of studies in MA No. of patients in MA Eradication rates by ITT Eradication rates odds ratio (95 % CI) by ITT Quality assessmentb
Zhang et al. 2008 China [25] May 2008 HP infection; naïve to treatment; PUD/NUD China (8), Italy (3) Levofloxacin-containing triple: levofloxacin+ Standard triple: clarithromycin+ 11 1926 Not reported 1.56 (1.25–1.94) 0
+same PPI(Ome/panto/esome) + another one antibiotic (furazolidone/amoxicillin/azithromycin/metronidazole/tinidazole)
Dong et al. 2009 China [33] May 2009 HP infection; naïve to treatment China (4), Italy (5), Korea, Russia, France, Croatia, US Azithromycin-containing triple: azithromycin+ + one antibiotic (levofloxacin/amoxicillin/metronidazole)+ Azithromycin NOT-containing triple: + two antibiotics (amoxicillin/clarithromycin/metronidazole/tinidazole)+ 14 1431 72.0 % vs. 69.8 % 1.17 (0.64–2.14) +
+same PPI (ome/esome/lanso/panto)
Yuan et al. 2009 China [34] Dec 2008 HP infection; naïve to treatment Italy, Croatia, Turkey, China Moxifloxacin-containing triple: moxifloxacin+ Clarithromycin-containing triple: clarithromycin+ 4 772 84.1 % vs. 73.6 % 1.13 (1.01–1.27)a +
+ same PPI (esome/lanso/ome) + another same regimen (amoxicillin/tinidazole/metronidazole/bismuth-)
Zhang et al. 2013 China [47] March 2012 HP infection; PUD/NUD/others; either naive or with previous treatment failures Korea (2), Croatia (2), China, Italy, Turkey Moxifloxacin-containing triple OR Quadruple: moxifloxacin + amoxicillin/metronidazole/tinidazole +/− RBC+ Standard triple or quadruple: (+/−)Bismuth/RBC + metronidazole/tinidazole/clarithromycin/amoxicillin+ 7 1263 79.0 % vs. 68.3 % 1.82 (1.17–2.81) +
+ same PPI (esome/ome/rabe/lanso)
Croatia, Turkey, Italy First-line First-line 3 717 Not reported 1.80 (0.71–4.55)
Moxifloxacin-containing triple OR Quadruple: moxifloxacin + amoxicillin/metronidazole/tinidazole (+/−) RBC+ Standard triple or quadruple: (+/−) Bismuth/RBC + metronidazole/tinidazole/clarithromycin/amoxicillin+
+ same PPI (esome/lanso)
Croatia, Korea (2), China Second-line Second-line 4 546 73.3 % vs. 60.2 % 1.78 (1.16–2.73)
Moxifloxacin-containing triple: moxifloxacin + metronidazole/amoxicillin+ Standard triple or quadruple: (+/−) Bismuth + metronidazole/tinidazole/clarithromycin+
+ same PPI (esome/ome/rabe)
Croatia, Korea (2), Turkey, Italy, China Moxifloxacin + amoxicillin (+/−) RBC+ Standard triple or quadruple: (+/−) Bismuth/RBC + metronidazole/tinidazole/clarithromycin/amoxicillin+ 6 810 Not reported 1.50 (0.95–2.38)
+ same PPI(esome/ome/rabe/lanso)
Croatia (2), Italy Moxifloxacin + metronidazole/tinidazole+ Standard triple or quadruple: (+/−) Bismuth/RBC + metronidazole/tinidazole/clarithromycin/amoxicillin+ 3 453 Not reported 3.00 (1.84–4.89)
+ same PPI (esome/ome/rabe/lanso)
Ye et al. 2014 China [35] August 2013 HP infection; naïve to treatment Germany, Egypt, Taiwan (2), China (2), Spain (2), Italy (2) Levofloxacin-containing triple: levofloxacin+ Standard triple: clarithromycin+ 10 2676 81.5 % vs. 77.2 % 1.28 (0.88–1.85) ++
+same PPI(Ome/lanso/esome) + another one antibiotic (amoxicillin/metronidazole)
Peedikayil et al. 2014 Saudi Arabia [36] March 2013 HP infection; naïve to treatment Egypt and Saudi Arabia, Taiwan (2), South Korea, China, Italy (2) Levofloxacin-containing triple: levofloxacin+ Standard triple: clarithromycin+ 7 1782 79.1 % vs. 81.4 % 0.97 (0.93–1.02)a +
+same PPI(Ome/lanso/esome) + another one antibiotic (amoxicillin/+metronidazole/clarithromycin/azithromycin)
Xiao et al. 2014 China [37] March 2013 HP infection; naïve to treatment, PUD/NUD/not reported Italy (2), China (3), Spain (2), Egypt and Saudi Arabia, Korea Levofloxacin-containing triple: levofloxacin+ Standard triple: clarithromycin+ 9 2512 80.2 % vs. 77.4 % 1.03 (0.94–1.13)a ++
+same PPI(Ome/lanso/esome) + another one antibiotic (amoxicillin/+metronidazole/clarithromycin/azithromycin)
Gou et al. 2014 China [26] December 2013 HP infection; naïve to treatment All from China Levofloxacin-containing triple: levofloxacin+ Standard triple: clarithromycin+ 21 2697 82.3 % vs.73.8 % 1.12 (1.08–1.16)a 0
No details reported
  1. HP H.pylori, PPI proton pump inhibitor, esome esomeprazole, lanso lansoprazole, ome omeprazole, panto pantoprazole, rabe rabeprazole, PUD peptic ulcer disease, NUD non-ulcer dyspepsia, MA meta-analysis, ITT intention to treat, CI confidence interval, RCT randomized controlled trials, RBC ranitidine bismuth citrate
  2. a Relative risk is reported here
  3. b Quality assessment: high quality (++): majority of criteria met, little or no risk of bias and results unlikely to be changed by further research. Acceptable (+): most criteria met, some flaws in the study with an associated risk of bias and conclusions may change in the light of further studies. Low quality (0): either most criteria not met or significant flaws relating to key aspects of study design, and conclusions likely to change in the light of further studies
  4. c Countries of included RCTs: the number in the bracket represents the number of trials from the same country if more than one trial exists